Maker of new gene therapy vector launches its second company, looking to zero in on rare skin conditions
The hub-and-spoke biotech Replay, which came onto the scene with $55 million in seed capital and a vision to launch four companies around its gene delivery platform, has already launched one company this year, but it is not looking to slow down as the year starts to wrap up.
Replay announced on Monday that the biotech is launching Telaria, a gene therapy company targeting rare skin diseases. The top therapy in Telaria’s pipeline is a treatment for recessive dystrophic epidermolysis bullosa (RDEB). This also marks the second of the four spinoffs that Replay is planning to launch by leveraging its “high payload capacity” herpes simplex virus (HSV) delivery vector.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.